KLAS Contact
Contact KLAS
Contact KLAS
2022 BEST IN KLAS
Preferences
Related Series
2021
2019
2017
2014
2012
Related Segments
Related Products
Related Vendors
Related Articles
Epic Pharmacy Solutions 2020
What Progress Has Epic Made with Medication Inventory and IV Workflow Management?
Author
Jackson Tate
Author
Paul Warburton
Current Time Inside Cache Tag Helper: 5/29/2022 6:45:34 AM and Model.reportId = 1703
Despite pressure to take an Epic-first approach to software decisions, many pharmacies at Epic organizations have held on to third-party products due to the relative immaturity of some of Epic’s more recently developed pharmacy solutions. However, Epic has put significant focus on broad pharmacy development (the only enterprise EMR vendor to have done so), and customers want to know—is it time to switch? To answer this question, this report explores medication inventory management (MIM) and IV workflow management—the two areas where Epic has focused much of their development efforts—to validate what capabilities these modules deliver and where gaps still exist.if you don't have a login, getting started is easy.
Key Findings
- Overall Progress Report: Technology Development Slow and Steady; Workflows and Optimization Left to the Customer
- Medication Inventory Management (Willow Inventory)
- Willow Tracks In-Scope Medications Well; Gaps Remain with Reporting
- Inventory Data from Third-Party Sources Often Incomplete
- IV Workflow Management (IV Dispense Prep)
- IV Dispense Prep Meets Core Needs; Lacks More Advanced Capabilities Out of the Box
- Epic Pharmacy Ecosystem
- Epic’s Pharmacy Functionality Delivers Breadth but Not Depth
Writer
Elizabeth Pew
Designer
Madison Fujimoto
Project Manager
Mary Brown
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2022 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.